# KarMMa-2 (NCT03601078)

> An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03601078
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: bb2121; Lenalomide; Talquetamab
- Enrollment: 312
- Primary outcome: Overall response rate (ORR)- Cohort 1
- Primary outcome: Complete response (CR) rate - Cohort 1b, 2a, 2b, 2c, and Cohort 3

## Commentary we found

- YouTube: 28
- Podcasts: 15
- X threads: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=karmma-2-nct03601078

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03601078", "email": "<work email>"}; the inbox owner confirms by the emailed link.